What's in Laboratoires NEGMA's pipeline?

Laboratoires NEGMA has 3 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Laboratoires NEGMA's portfolio?

Top competitors by shared drug class: IRCCS Eugenio Medea, Merck Sharp & Dohme LLC, The HIV Netherlands Australia Thailand Research Collaboration.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/laboratoires-negma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Laboratoires NEGMA — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Laboratoires NEGMA pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Diacerhein	Diacerhein	marketed		Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase	Other
ART 44	ART 44	phase 3	Non-nucleoside reverse transcriptase inhibitor	HIV-1 reverse transcriptase	Infectious Diseases
ART 50	ART 50	phase 3	Non-nucleoside reverse transcriptase inhibitor	HIV-1 reverse transcriptase	Infectious Diseases

Therapeutic area mix

Infectious Diseases · 2
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

IRCCS Eugenio Medea · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
The HIV Netherlands Australia Thailand Research Collaboration · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Laboratoires NEGMA:

Cite this brief

Drug Landscape (2026). Laboratoires NEGMA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratoires-negma. Accessed 2026-06-10.